Vanguard Group’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-2,948,165
| Closed | -$113M | – | 4604 |
|
|
2023
Q2 | $113M | Buy |
2,948,165
+100,330
| +4% | +$2.58M | ﹤0.01% | 1790 |
|
|
2023
Q1 | $65.9M | Buy |
2,847,835
+55,261
| +2% | +$1.32M | ﹤0.01% | 2041 |
|
|
2022
Q4 | $73.2M | Buy |
2,792,574
+392,808
| +16% | +$8.7M | ﹤0.01% | 1977 |
|
|
2022
Q3 | $47.2M | Buy |
2,399,766
+37,190
| +2% | +$746K | ﹤0.01% | 2211 |
|
|
2022
Q2 | $41.3M | Buy |
2,362,576
+533,204
| +29% | +$8.37M | ﹤0.01% | 2285 |
|
|
2022
Q1 | $29.9M | Buy |
1,829,372
+42,858
| +2% | +$583K | ﹤0.01% | 2565 |
|
|
2021
Q4 | $29.1M | Buy |
1,786,514
+351,818
| +25% | +$5.01M | ﹤0.01% | 2643 |
|
|
2021
Q3 | $18.3M | Buy |
1,434,696
+44,086
| +3% | +$580K | ﹤0.01% | 2913 |
|
|
2021
Q2 | $19.6M | Buy |
1,390,610
+185,043
| +15% | +$2.96M | ﹤0.01% | 2860 |
|
|
2021
Q1 | $18.7M | Buy |
1,205,567
+24,031
| +2% | +$392K | ﹤0.01% | 2819 |
|
|
2020
Q4 | $18.7M | Buy |
1,181,536
+542,846
| +85% | +$8.19M | ﹤0.01% | 2666 |
|
|
2020
Q3 | $7.76M | Buy |
638,690
+126,328
| +25% | +$1.69M | ﹤0.01% | 2921 |
|
|
2020
Q2 | $5.92M | Buy |
512,362
+36,569
| +8% | +$504K | ﹤0.01% | 3029 |
|
|
2020
Q1 | $6.52M | Buy |
475,793
+58,835
| +14% | +$696K | ﹤0.01% | 2829 |
|
|
2019
Q4 | $2.46M | Sell |
416,958
-29,057
| -7% | -$158K | ﹤0.01% | 3390 |
|
|
2019
Q3 | $2.36M | Sell |
446,015
-57,412
| -11% | -$381K | ﹤0.01% | 3397 |
|
|
2019
Q2 | $3.88M | Buy |
503,427
+11,052
| +2% | +$168K | ﹤0.01% | 3259 |
|
|
2019
Q1 | $9.8M | Sell |
492,375
-161,628
| -25% | -$2.82M | ﹤0.01% | 2834 |
|
|
2018
Q4 | $8.63M | Sell |
654,003
-151,886
| -19% | -$3.03M | ﹤0.01% | 2839 |
|
|
2018
Q3 | $29.6M | Buy |
805,889
+72,503
| +10% | +$2.33M | ﹤0.01% | 2396 |
|
|
2018
Q2 | $25.7M | Buy |
733,386
+37,569
| +5% | +$1.44M | ﹤0.01% | 2458 |
|
|
2018
Q1 | $32.4M | Buy |
695,817
+4,632
| +0.7% | +$170K | ﹤0.01% | 2301 |
|
|
2017
Q4 | $25.9M | Buy |
691,185
+138,108
| +25% | +$6.03M | ﹤0.01% | 2381 |
|
|
2017
Q3 | $29.5M | Buy |
553,077
+50,678
| +10% | +$3.01M | ﹤0.01% | 2312 |
|
|
2017
Q2 | $28.6M | Buy |
502,399
+25,816
| +5% | +$1.3M | ﹤0.01% | 2300 |
|
|
2017
Q1 | $25.6M | Buy |
476,583
+9,768
| +2% | +$552K | ﹤0.01% | 2341 |
|
|
2016
Q4 | $26.6M | Buy |
466,815
+27,012
| +6% | +$1.63M | ﹤0.01% | 2287 |
|
|
2016
Q3 | $27.3M | Buy |
439,803
+80,835
| +23% | +$5.71M | ﹤0.01% | 2223 |
|
|
2016
Q2 | $20.3M | Buy |
358,968
+47,585
| +15% | +$2.89M | ﹤0.01% | 2331 |
|
|
2016
Q1 | $19.9M | Buy |
311,383
+10,898
| +4% | +$882K | ﹤0.01% | 2306 |
|
|
2015
Q4 | $42.3M | Buy |
300,485
+276,546
| +1,155% | +$37.6M | ﹤0.01% | 1959 |
|
|
2015
Q3 | $2.32M | Buy |
23,939
+15,339
| +178% | +$1.83M | ﹤0.01% | 3309 |
|
|
2015
Q2 | $1.3M | Buy |
+8,600
| New | +$1.42M | ﹤0.01% | 3578 |
|
Vanguard Group's KDNY Position: Q3 2023 in Review
Vanguard Group sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 2,948,165 shares — an estimated $113M sold.
Vanguard Group first reported a position in KDNY in Q2 2015 and held it in 33 quarters. The position peaked at $113M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.
- Vanguard Group reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Vanguard Group sold 2,948,165 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $113M.
- Vanguard Group first reported a position in Chinook Therapeutics, Inc. Common Stock in Q2 2015 and held it in 33 quarters.
- Vanguard Group's Chinook Therapeutics, Inc. Common Stock position peaked at $113M in Q2 2023.
- 2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.
Based on Vanguard Group's 13F filing for Q3 2023, filed 14 Nov 2023.